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Summary
Acute liver failure (ALF) or fulminant hepatitis is a rare, yet severe outcome of infection with hepatitis B virus (HBV) that carries a high mortality rate. The occurrence of a lifethreatening condition upon infection with a prevalent virus in individuals without known risk factors is suggestive of pathogen-specific immune dysregulation. In the absence of established differences in HBV virulence, we hypothesized that ALF upon primary infection with HBV could be due to rare deleterious variants in the human genome. To search for such variants, we performed exome sequencing in 21 previously healthy adults who required liver transplantation upon fulminant HBV infection and 172 controls that were positive for anti-HBc and anti-HBs but had no clinical history of jaundice or liver disease.
After a series of hypothesis-driven filtering steps, we searched for putatively pathogenic variants that were significantly associated with case-control status. We did not find any causal variant or gene, a result that does not support the hypothesis of a shared monogenic basis for human susceptibility to HBV-related ALF in adults. This study represents a first attempt at deciphering the human genetic contribution to the most severe clinical presentation of acute HBV infection in previously healthy individuals.
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| INTRODUC TI ON
Hepatitis B virus (HBV) is a common human pathogen that attacks the liver and can cause both acute and chronic disease. There is high inter-individual variability in the clinical presentation of HBV infection, which ranges from self-limited to fulminant acute disease and from mild chronic hepatitis to liver cirrhosis and hepatocellular carcinoma. 1 Differences in viral or environmental factors only explain a fraction of this variability. [2] [3] [4] [5] Previous studies have identified some human genetic factors that play a modulating role in the clinical course `of HBV infection. 6, 7 However, our understanding of host genetic influences on the disease is still very limited.
Fulminant hepatitis or acute liver failure (ALF) is defined as the rapid development of liver injury leading to severe impairment of the synthetic capacity and to hepatic encephalopathy in patients without previous liver disease. 8, 9 ALF due to HBV infection, or fulminant hepatitis B, is observed in less than 0.1% of infected individuals but carries a high mortality and is an indication for urgent liver transplantation. [10] [11] [12] [13] [14] [15] Such an unusual clinical presentation fits the definition of an extreme phenotype. Electing patients with extreme phenotype increases the power to detect causal gene as variants as these patients are more likely to carry alleles with profound functional consequences that are otherwise very rare in the population, due to purifying selection. [16] [17] [18] [19] [20] In this study, we used exome sequencing and statistical analysis in a cohort of 21 cases and 172 controls to search for human genetic variants conferring extreme susceptibility to HBV. Cases were previously healthy adults who required liver transplantation for fulminant hepatitis B, and controls were HBV-infected adults who did not develop fulminant hepatitis ( Figure 1 ). 
| ME THODS

| Study participants
| Control population
One hundred seventy-two controls were selected from our in-house database of exome-sequenced individuals. They were adults of 
| Variant calling
We used Genome Analysis Toolkit (GATK) 24 
| Variant effect prediction, frequency estimation and filtering
We used SnpEff 26 version 4.3T to predict the functional impact of variants. As a single variant can have several predicted effects, we only considered the most severe effect for each variant according to SnpEff order of impact severity. We used genome aggregation database (gnomAD) to assign minor allele frequency (MAF) to variants (gnomAD, includes 123 136 exome sequences and 15 496 whole-genome sequences).
27
For variants that were not present in gnomAD were assigned MAF = 1-e8 to avoid having −log(0) in the following burden analysis. Only biallelic variants that were flagged as PASS by GATK and were called in all cases and all controls were included in the analysis. Known polymorphic genes and genes in noisy alignment regions were excluded from the analysis.
28-30
We restricted all the downstream analyses to protein modifying variants (missense, inframe indels, frameshift indels, splice site disrupting, nonsense). All analyses were done on both rare (MAF ≤ 0.01) and low-frequency (MAF ≤ 0.05) variants. We refer to variants that passed above filtering criteria as putatively pathogenic variants.
| Single-variant association tests
We used Fisher's exact test to look for association of single variants with case-control status. Each variant was given an allele count based on the number of alternate alleles G ij ϵ {0,1,2}, where G ij is the genotype of variant j in individual i. We summarized the reference and alternate allele counts for cases and controls, into 2x2 contingency tables. These tables were analysed using one-tailed Fisher's exact test. We used Bonferroni correction to correct for multiple testing.
| Gene burden association tests
Gene burden test was performed using GMMAT 31 version 0.7-1, a generalized linear mixed model framework as follows:
where H is an n-vector of case-control status for n individuals, W is an n-vector of gender covariate and C is an n-vector of the gene burden scores. M is an n-vector of random effects. τ k is the variance component parameters, and V k are known n × n matrices. We ran this model using an n × n kinship coefficients matrix calculated using PC-Relate. 32 We used Bonferroni correction to correct for multiple testing. To calculate the gene burden scores, we used two different methods:
| Binary collapsing method
Each gene was given a burden score of zero if no putatively pathogenic variant was present in the gene and a gene burden score of one otherwise:
where G ij ϵ {0,1,2} is the genotype of variant j in individual i, and C i is the gene burden score for individual i. This approach is based on the cohort allelic sum test (CAST) method. 
| Weighted sum collapsing method
First, each gene was given a burden score as follows:
where j ϵ {0,1,2, …, m} is the mth variant per gene, and
is the genotype of variant j in individual i; AF i -gnomAD is the minor allele frequency of j in gnomAD, and C i is the gene burden score for individual i. This approach is based on the Madsen and Browning weighted sum method. 
| RE SULTS
| Study participants
Of the 21 cases, 13 (62%) were female. The median age at transplantation was 36.5 years (range 22-58). Of 21 cases, 16 (76%) were European, four (19%) were Asian and one (5%) was African ( Figure S1 ).
| Exome sequencing, variant calling and variant filtering
Exome sequencing data were generated from DNA extracted from whole blood for all study participants. On average per sample, 96%
of reads passing filtering criteria were unique (not marked as duplicate). Ninety-seven percent of unique reads could be aligned to the human reference genome GRCh37. The mean on-bait coverage was 73x, with 99% of target bases reaching at least 2x coverage, 97%
of target bases achieving at least 10x coverage and 84% achieving at least 30x coverage. 205 642 variants were detected after GATK quality control filtering including 520 novel variants. The average transition to transversion ratio (Ti/Tv) was 2.66, and the average heterozygous to homozygous ratio was 1.5. A total of 38,062 lowfrequency variants (MAF≤0.05) passed filtering criteria including 31 620 rare variants (MAF ≤0.01, Table 1 ).
| Single-variant associate analysis
All putatively pathogenic variants were tested for association with case-control status using Fisher's exact test. We first restricted the analysis to rare variants (MAF ≤0.01) and European cases only.
One variant passed the Bonferroni correction threshold (P-value <1.6e-6). The variant was a missense SNV in IGSF3 (rs78806598, P-value = 1.8e-18). Visualizing the aligned reads for this variant convinced us that this variant is called due to misalignment. This gene was excluded from our further analyses. Expanding the analysis to include the five non-European cases and the low-frequency variants did not lead to discovery of any significant associations (Tables S1-S3 ).
| Gene-based association analysis
A total of 11 595 genes were included in the gene burden analysis. Two different burden scores were calculated for each gene using the approached described in the methods section. Using the weighted sum method, SLC29A1 had the lowest P-value (Pvalue = 1.7e-5). CTSW had the lowest P-value in binary collapsing method (P-value = 1.8e-5). However, none of these genes passed the Bonferroni correction threshold (P-value <2.5e-6 for 20 000
protein coding genes, Tables S4-5 ). Including the low-frequency variants (12 295 genes in total) did not change these results. The top associations including low-frequency variants were ADAM32
(P-value = 1.7e-5) and PREX2 (P-value = 8.7e-6) in for weighted sum method binary collapsing method, respectively (Tables S6-7) .
Overall, the results from the two collapsing methods and the results between rare variants (MAF ≤0.01) and low-frequency variants (MAF ≤0.05) analyses were highly concordant (Figure 2 , Figure S2 ). Because this is an extremely rare clinical event, we hypothesized that it could be the first manifestation of a rare monogenic defect, resulting in pathogen-specific immune dysregulation.
TA B L E 1
| D ISCUSS I ON AND CON CLUS I ON
We used exome sequencing to systematically search for rare, putatively pathogenic variants that could explain extreme susceptibility to HBV infection. We analysed the genetic variants present in the exomes of 21 liver transplant recipients and compared them to 172 controls who were exposed to HBV but did not develop fulminant hepatitis B. First, we performed a single-variant association analysis using Fisher's exact test. Fisher's exact test is a conservative test of association but guarantees type I error control for small sample sizes. 44 We found one significant association (P-value <1.4e-6) in one gene: IGSF3. However, the manual inspection of the mapped reads in the region demonstrated that this variant was wrongly called, due to a mapping error. False-positive incidental findings are a major problem in small-scale exome sequencing studies. 28 Previous studies have proposed guidelines to avoid misinterpretations and erroneous reports of potential causality due to false-positive findings. 29, 30 Our results show that even after applying these guidelines, it is important to ensure the quality of final findings by visualizing the mapped regions and manually verifying the quality of each variant call.
Rare variant association studies are usually underpowered. To enrich association signals and reduce the penalty of multiple testing correction, it is common to aggregate information across multiple rare variants within a region (gene, exon, sliding window, etc.) and test for the association of all variants in the region with the phenotype of interest. 45 We performed gene-based association analysis using two different aggregation methods: weighted sum collapsing and binary collapsing. Both methods assume that all the variants included in the test have the same direction of effect (increasing disease risk in our scenario) and thus are underpowered to detect disease-gene associations whether variants exert their effects in opposite directions. Binary collapsing assumes that all putatively pathogenic variants have the same effect size. Weighted sum collapsing assumes that rarer variants have larger effect sizes and that the risk of disease is a function of the sum of the variant effect sizes. We did not find any genes to be significantly associated with case-control status. The P-values and the top-ranked genes in both analyses were highly concordant (Figure 2, Figure S2 ). The high correlation between the P-values of weighted sum and binary collapsing methods suggests that most individuals carry only one putatively pathogenic variant per gene. This implies that larger sample sizes or linkage studies in families with multiple affected individuals will be needed to increase statistical power for detecting potential associations between rare variants and HBV-related ALF.
We did not identify any genetic variant conferring monogenic susceptibility to fulminant hepatitis B in adults. Our results suggest that ALF upon primary infection with HBV is likely to be multifactorial. This conclusion is in line with a previous exome sequencing study of fulminant hepatitis A, which also failed to find any convincing casual gene or genetic variant. 46 Our failure to detect a
Mendelian cause for fulminant hepatitis B, despite previous success for comparable phenotypes, could be due to a number of factors and limitations of our study. Due to our recruitment criteria, we did not have access to information about the viral genome. HBV genetic variation has previously been shown to be associated with disease severity and infection outcome, but these results remain controversial. In particular, mutations in the pre-core and basal core promoter regions of the HBV genome were associated with ALF in some studies, [52] [53] [54] but not in others. [54] [55] [56] [57] The inclusion of viral genome information might allow for the stratification of patients based on known HBV mutations, thus increasing the signal-to-noise ratio in human genetic analyses.
This study represents the first attempt at identifying human ge- 
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